Detailed Information on Publication Record
2016
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Tomáš PAVLÍK, Veronika VESKRNOVA et. al.Basic information
Original name
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Authors
BUCHLER, Tomas (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, guarantor, belonging to the institution), Alexandr POPRACH (203 Czech Republic), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Veronika VESKRNOVA (203 Czech Republic), Michaela HONZIRKOVA (203 Czech Republic), Milada ZEMANOVA (203 Czech Republic), Ondrej FIALA (203 Czech Republic), Kateřina KUBÁČKOVÁ (203 Czech Republic), Ondřej SLABÝ (203 Czech Republic), Marek SVOBODA (203 Czech Republic), Rostislav VYZULA (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution) and Bohuslav MELICHAR (203 Czech Republic)
Edition
European Urology, Amsterdam, Elsevier Science Inc. 2016, 0302-2838
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 16.265
RIV identification code
RIV/00216224:14110/16:00088841
Organization unit
Faculty of Medicine
UT WoS
000380754000024
Keywords in English
Renal cell carcinoma; Targeted therapy; Complete response; Survival
Tags
Tags
International impact, Reviewed
Změněno: 27/9/2016 11:33, Ing. Mgr. Věra Pospíšilíková
Abstract
V originále
BACKGROUND: It is currently not known whether treatment with anti-vascular endothelial growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued in patients achieving a complete response (CR). OBJECTIVE: To assess outcomes for patients with mRCC achieving CR on targeted therapy (TT) and the survival of patients discontinuing TT after CR. DESIGN, SETTING, AND PARTICIPANTS: A national registry was used to identify patients achieving CR during first-line TT using bevacizumab, sunitinib, sorafenib, or pazopanib. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcomes were analysed using a log-rank test. RESULTS AND LIMITATIONS: A total of 100 patients achieving CR were identified out of 2803 patients. The median time to CR was 10.1 mo. Median progression-free survival (PFS) from TT initiation was 3.8 yr (95% confidence interval [CI] 2.9-4.6 yr) and the 5-yr overall survival (OS) was 80% (95% CI 70-91%). Patients discontinuing TT within 1 mo after achieving CR and those continuing TT beyond CR had similar OS (CI for difference in 2-yr post-CR OS -13% to 19%; p=0.3) and PFS (CI for difference in 2-yr post-CR PFS -29% to 17%; p=0.7). The limitations include the retrospective, registry-based data analysis. CONCLUSIONS: Achievement of CR on TT for mRCC was associated with excellent long-term prognosis. No significant differences in post-CR survival were observed between patients discontinuing TT after the date of CR and those who continued on TT, although the wide CIs cannot exclude important differences between the groups. PATIENT SUMMARY: According to this registry-based analysis, patients with metastatic renal cancer with no signs of disease (complete response) after treatment with targeted agents experience excellent long-term survival even if the treatment does not continue beyond the date of complete response.
Links
| NV15-34678A, research and development project |
|